Search Results

You are looking at 71 - 80 of 1,100 items for :

  • "breast cancer" x
  • All content x
Clear All
Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

control groups that adhered to standard care in the concurrent NCCN Guidelines. Worldwide, breast cancer is the most commonly researched cancer, accounting for the highest proportion of clinical trials, 7 and therefore is an ideal group to analyze

Full access

Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, and Harold J. Burstein

Background Advances in breast cancer treatment have significantly improved survival for patients with metastatic breast cancer (MBC) from 1 to 2 years in the 1970s to 1 to 3 years today. 1 - 3 However, MBC remains incurable, and the goals of

Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia

Although breast cancer in young women is rare overall, it accounts for a significant proportion of all cancers in women aged ≤40 years. 1 It is estimated that in 2015, 5% of all new invasive breast cancer cases and 3% of all breast cancer deaths

Full access

Jatinder Singh, Stephen B. Edge, Ermelinda Bonaccio, Kathleen Trapp Schwert, and Brian Braun

the OFI project charter to focus on access and wait times in the Breast Cancer Center. The team that coordinated the improvement was the Breast Product Line, co-led by the clinical chief and the breast imaging chair. This leadership group meets every

Full access

Gabrielle B. Rocque, Courtney P. Williams, Bradford E. Jackson, Stacey A. Ingram, Karian I. Halilova, Maria Pisu, Kelly M. Kenzik, Andres Azuero, Andres Forero, and Smita Bhatia

treatment regimens to specify recommendations. 2 Previous evaluations of NCCN Guidelines have focused on the use of specific, individual medications considered off-label or nonconcordant. In breast cancer, >10% of patients receive a medication not listed

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

) include evidence-based, physician-recommended treatments. Concordance with NCCN Guidelines for Breast Cancer is increasingly recognized as a marker of high-quality cancer care. 1 , 2 Specifically in metastatic breast cancer (MBC), >45 guideline

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

Background Breast cancer is a heterogeneous group of diseases and encompasses a variety of molecular and morphologic subtypes. Triple-negative breast cancer (TNBC) represents approximately 15% to 20% of all breast cancers. 1 Compared with hormone

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

Amplification or overexpression of the HER2 gene comprises 15% to 25% of early-stage breast cancers. 1 , 2 Associated with an aggressive phenotype, survival for HER2-positive (HER2+) breast cancer has significantly improved with the use of HER2

Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner

Background Aromatase inhibitors (AIs), tamoxifen, and the sequential use of these agents are all standard options for adjuvant hormonal therapy (HT) for postmenopausal women with early-stage, estrogen receptor (ER)–positive breast cancer. At

Full access

Ania Syrowatka, Sue-Ling Chang, Robyn Tamblyn, Nancy E. Mayo, and Ari N. Meguerditchian

-related morbidity and mortality, as well as quality of life. 4 – 6 Most new breast cancer diagnoses occur in women older than 60 years, with the proportion expected to increase with demographic changes in age distributions. 7 Distress and pain are expected to